Loblaw Companies (LBLCF) Q2 2026 Earnings Report

The call emphasized broad operational strength: solid revenue and adjusted EPS growth, improving adjusted EBITDA, robust pharmacy momentum, strong e-commerce expansion, successful store openings (including an exceptionally strong T&T California debut), and a strengthened capital-return program. Management also highlighted positive early signs from GLP-1 generics as a potential gross margin tailwind. Near-term negatives were acknowledged but appear manageable: ramp costs for new distribution capacity and stores, some category/timing headwinds (Easter shift, tobacco/liquor, tariff timing), a one-month reporting timing impact from the PC Financial sale, and external risks like fuel-price volatility. Overall, the positives and strategic tailwinds substantially outweigh the manageable short-term headwinds.

Loblaw reiterated that it expects Retail earnings to grow faster than sales and guided to adjusted net earnings per common share growth in the high single digits for the year despite a Q3 timing headwind (only one month of EQB earnings will be recognized in Q3); management expects continued consistent top‑line sales growth in Q3, ~75 store openings this year, ongoing consistent free cash‑flow growth and a larger NCIB (now targeting $2.1 billion of share repurchases for the year, up $200 million; $552 million repurchased in Q2 and $1.2 billion year‑to‑date), and plans to increase its EQB stake from ~19.9% toward ~25%; they also expect GLP‑1s going generic to drive double‑digit revenue growth in 2027 with gross profit dollars and margin rising by more than top‑line growth, and noted strong returns (ROE 27.2%, ROC 12.5%) alongside confidence in gross margin outlook.